Render Target: STATIC
Render Timestamp: 2025-01-08T12:21:44.459Z
Commit: 199712eb9daea12d88cc0e67894a8a09f475f8cb
XML generation date: 2024-09-30 01:55:09.749
Product last modified at: 2025-01-01T09:04:21.799Z
Cell Signaling Technology Logo
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

FLCN (D14G9) Rabbit mAb #3697

Filter:
  • WB
  • IP

    Supporting Data

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa) 70
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    • IP-Immunoprecipitation 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Immunoprecipitation 1:100

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    FLCN (D14G9) Rabbit mAb detects endogenous levels of total FLCN protein.

    Species Reactivity:

    Human

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with recombinant human FLCN protein.

    Background

    The protein folliculin (FLCN) is encoded by the BHD (Birt-Hogg-Dube) gene that is altered in BHD Syndrome, a disorder characterized by the presence of benign connective tissue tumors known as fibrofolliculomas, renal tumors and lung cysts (1). Clinical similarities between BHD and hamartoma-producing disorders caused by Tsc2, PTEN and LKB1 gene mutations indicate that FLCN might also be important in nutrient and energy sensing through the mTOR pathway (2). This model is supported by studies demonstrating a direct correlation between the down regulation of BHD and a reduction in mTOR associated phosphorylation of S6 ribosomal protein (3). Mutation of either the TSC1 or TSC2 gene results in elevated mTOR activity (4) while deletion of the Tsc2 and BHD homologs in yeast have opposing effects on both mTOR signaling and amino acid homeostasis (5). BHD knock-out mice develop cysts and renal cell tumors similar to those found in BHD patients along with low levels of phosphorylated S6 ribosomal protein (3). Based on these finding, it appears that either abnormally high or abnormally low levels of mTOR signaling might contribute to renal cell carcinogenesis.
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.